Literature DB >> 28195233

Haematological cancer: Idelalisib for CLL - risky benefit.

Diana Romero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28195233     DOI： 10.1038/nrclinonc.2017.17

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Authors:  Andrew D Zelenetz; Jacqueline C Barrientos; Jennifer R Brown; Bertrand Coiffier; Julio Delgado; Miklós Egyed; Paolo Ghia; Árpád Illés; Wojciech Jurczak; Paula Marlton; Marco Montillo; Franck Morschhauser; Alexander S Pristupa; Tadeusz Robak; Jeff P Sharman; David Simpson; Lukáš Smolej; Eugen Tausch; Adeboye H Adewoye; Lyndah K Dreiling; Yeonhee Kim; Stephan Stilgenbauer; Peter Hillmen
Journal:  Lancet Oncol       Date:  2017-01-28       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.